Dr.Kushagra Jain, J18189
Purpose: To study the efficacy of an intravitreal ranibizumab biosimilar Razumab in the management of macular edema.
Methods: A single-centre, retrospective study of 129 eyes who underwent monthly injections of Razumab for macular edema. The corrected distance visual acuity (CDVA) and central macular thickness (CMT) was assessed at baseline, and at 4, 8 and 12 weeks.
Results: The most common indication was diabetic macular edema (31%) followed by age-related macular degeneration and retinal vein occlusion. 65.89% were treatment naïve eyes. The baseline CDVA of 0.66 ± 0.495 (mean±SD, logMAR) improved to 0.46 ± 0.406, 0.39 ± 0.306 and 0.37 ± 0.313 at 4,8 and 12 weeks respectively. The baseline CMT (µm) of 543.69 ± 134.595 improved to 407.84 ± 95.666, 358.97 ± 105.029 and 344.78 ± 112.776 at 4, 8 and 12 weeks. The mean IOP was 14.34 ± 2.802 mmHg at 12 weeks.
Conclusion: Razumab is a viable and affordable option for macular edema treatment, with good clinical outcomes and compliance.
Leave a Comment